TRXX news
Dr Vicki Hufnagel Leads The Stem Cell Revolution At The Top of Publicly Traded Company
On Monday April 27, 2009, 9:45 am EDT
Buzz up! Print
BOCA RATON, FL, April 27 /PRNewswire-FirstCall/ - Stem Cell Assurance, Traxxec Inc. (The Company) (Other OTC:TRXX.PK - News) today updated shareholders with regard to the new Board and Officers.
Dr. Vikki Hufnagel has a long and distinguished scientific research history and has contributed to many significant breakthroughs in Patient's Rights, and Women's Rights, in Health Care and Public Law. Dr. Hufnagel has the honor of being the first physician in the United States to co-author state laws to provide informed consent to patients. She has also worked with members of Congress on "Patient Rights" as a Constitutional issue. Dr. Hufnagel has lectured widely and has authored such best-selling books as '"No More Hysterectomies", and articles that present complex scientific material in an easy-to-understand manner for the everyday reader. Her medical expertise, visionary outlook, and compassion have led her to be on many national television programs, such as Oprah, as an expert guest in the field of Medicine.
During her undergraduate work at the University of California Berkeley Dr. Hufnagel realized the life changing benefits of genetic and cellular research taking place, and the possible future medical breakthroughs that might arise from such research. As a student at the University of California San Francisco School of Medicine she worked with the Pediatrics Endocrine group that developed Human Growth Hormone for the treatment of short stature, later that team formed Genentech. She went on to be named a National Institutes of Health Fellow in Reproductive Genetics under Dr. Mitchell Golbus at University of California San Francisco during the early years of in utero fetal diagnosis and treatment. In the lab, her research focused on cellular genetic and biochemical determinations. During her years at Cedars Sinai Medical Center in Los Angeles, she co-authored several major million-dollar grant requests that were funded, and later served as an investigator on those projects. Dr. Hufnagel later volunteered with the March of Dimes, authoring grants in the field of Nerve Growth Hormone and its role in neural tube defects. She performed pioneering work in women's hormonal health care and first compounded in 1983, and has subsequently created and compounded Natural Cyclic Hormones. Dr. Hufnagel has also worked as an experimental surgeon, perfecting new organ preserving operations. Her current work includes developing a medical treatment for HPV.
Dr. Hufnagel has continued both her medical education and the expansion of her research by obtaining degrees in Alternative and Naturopathic Medicine. As the field of Medicine was drastically in flux, in 2004 she focused her studies in Philosophy, Theology, and Bioethics with a belief that these disciplines would be significant in Research and Development as stem cell and other cellular technologies advanced. Dr. Hufnagel's background offers a unique global outlook in stem cell research and the philosophy of ethical healing.
"I am blessed to be in an area of research and development that has so much life-saving potential. Stem cell work can help us to prevent and cure disease, ameliorate suffering from disease, and unlock the codes of cell growth, metamorphosis, and regeneration. My expertise and position within Stem Cell Assurance will allow me to access the lab where I will be part of the on-going research. We are committed to having the largest and most comprehensive data base on stem cell work available for public access. As a Bioethicist I will be reaching out to the Medical Bioethics community for guidance and support regarding Stem Cell Assurance's future endeavors. It is a time for healing and for deep compassion in the human condition and a time for Science to actively participate in a compassionate way to benefit the World."
About Stem Cell Assurance - www.stemcellassurance.com
Stem Cell Assurance (SCA) is one of the nation's first companies solely established to make available a comprehensive set of Adult Stem Cell services to consumers. SCA will provide genetic profile services and consultations, adult stem cell therapies, adult stem cell research as well as stem cell collection, storage services and cosmetic products. SCA is strategically positioned to enhance the scope of services available to consumers for collection, processing, cryopreservation and storage system. The company specializes in collecting, testing, and banking an individual's own healthy adult stem. These stem cells will serve as the basis for emerging personalized immunological and regenerative therapies. It is very important to note that Stem Cell Assurance is not involved in the use of embryonic stem cells. Stem Cell Assurance works to ensure that the client's adult stem cells will always be available for future use in sustaining life and battling disease. The company is headquartered in Boca Raton, Florida. For more information about Stem Cell Assurance, please visit our website at www.stemcellassurance.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
